Effect of Anagliptin versus Sitagliptin on Renal Function: Subanalyzes from the REASON Trial.

ABSTRACT:

Purpose

The effects of two types of dipeptidyl peptidase-4 (DPP-4) inhibitors on renal function remain unclear. Thus, we investigated the effect of anagliptin (ANA) and sitagliptin (SITA) on renal function in patients with type 2 diabetes who participated in the randomized evaluation of ANA versus SITA on low-density lipoprotein-cholesterol (LDL-C) in diabetes (REASON) trial.

Patients and methods

We measured the estimated glomerular filtration rate (eGFR) and urinary albumin-creatinine ratio (UACR) before and after the REASON trial. ANA 200 mg/day was administered to 177 patients for 52 weeks, while SITA 50 mg/day was given to 176 patients. We investigated the relationship between differences in renal function and differences in hemoglobin A1c (HbA1c) levels, LDL-C levels, a

SUBMITTER: Teragawa H 

PROVIDER: S-EPMC8901417 | biostudies-literature | 2022

REPOSITORIES: biostudies-literature